Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conferences:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

Access:

Availability:

clear all | select all

Participation Type:

clear all | select all

Categories:

Showing session: reset

Thyroid Cancer and Autoimmunity

Browse by: Sort by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 1 of 1
Thyroid Cancer and Autoimmunity
Chair
Eyal Robenshtok, MD
Rabin Medical Center, Petah Tikva, Israel
Cepharanthine Blocks the Presentation of Thyroid & Islet Peptides in a Novel Humanized Autoimmune Polyglandular Syndrome Type 3 Variant (APS3v) Mouse Model
Cheuk Wun Li, PhD
Albert Einstein College of Medicine, Bronx, NY
Audience Q&A
MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)
Christine Do Cao, MD
CHRU, Hôpital Claude Huriez, Lille, France
Audience Q&A
Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients ? : Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745)
Sophie Leboulleux, MD, PhD
Gustave Roussy, Villejuif, France
Audience Q&A
Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
Christopher Muir, MBBS, FRACP
The University of Sydney, Sydney, Australia
Audience Q&A
 
Paid users only - purchase
Slides + audio
 
 
Available
from ENDO 2021 on March 20, 2021 2:15 PM-3:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 1 of 1